Member Info for ZaphodBeeblebrox

I see I am not the only one who had a surprise about antibody use this morning.
First invested in April 2020, and have to say that Avacta is the tortoise in the covid test race.
Hopefully it can win in the end.
Good luck all, and hoping for better news on non-covid fronts shortly.

Good point on the Technical Transfer in December stated by Abingdon Health ABDX, shared by EbbsandFlows.
From ABDX RNS this morning regarding the AVACTA LFT "Abingdon confirms that it completed the technical transfer of the AffiDX® SARS-CoV-2 antigen lateral flow test assay product as planned. Technical transfer is the process of taking a developed product and optimising all processes and elements for mass manufacture. The final technical transfer batches were shipped to Avacta in mid-December 2021 with the products adhering to defined specifications and passing all quality control procedures."
"Abingdon scientists will work with Avacta to accelerate the process of replacing the antibody in the current assay format, and complete the process of technology transfer with this new specification."
I would suspect that the assessment of replacement antibody products is well underway and as TT has been achieved once I am sure it can be achieved again relatively quickly once a more effective antibody is found.
All tests targetting the S protein will have the same problems due to the many spike mutations on omicron. I was wondering if an antibody in the AVCT was even necessary, rather than 2 affimers targetting two sites? I thought the point of affimers was to remove reliance on large expensive molecules?
All of this should have been thought of by the company boffins of course.

Glad to see some signs of life from the BOD in recent weeks.
Still no tradeable shares in HL, for TLSA or ACMSY.
Wonder what the hell Dechert LLP have been doing on the delisting and transfer. Doesn't make them look any good does it?

Just saw this myself, Asianarket.

NEW YORK, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences (Nasdaq: TLSA) (“Tiziana”), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery, today announced that senior management will present at the Biotech Showcase Conference and be available for one-on-one meetings throughout the conference. The conference is being held virtually from January 10th -12th and also during January 17th -19th.

https://informaconnect.com/biotech-showcase/registration-options/

As mentioned by howezap at 0823, here is the post on the ADVFN board by thediddynen at 0715 today 5/1/2021, regarding sale proceeds.
"On the issue of the sale of Racecourse, Racecourse is owned by Projectore, a subsidiary of Xtract Resources. Unless I am missing something the way to return the cash to shareholders would be by issue of Projectore shares in specie to existing shareholders of Xtract. The acquirer then purchases the shares from Xtract shareholders. In effect shareholders will see the net transaction which is a cheque. That means that theree was no disposal of Racecourse, which means no CGT or Australian equivalent. While in the UK the transaction will be treated as a capital rather than income item, or in other words it will be treated as a capital gain. Shareholders will still retain their shares in Xtract which means that there will need to be a capital apportionment of cost to determine the capital gain if the shares are held outside an ISA. Just need to get to that start line!"

The good new continues.
The long term prospect at Bibemi look better and better.
Will the sp react at all is the question, although one would think it should!

Dr Suzy Dilly, CEO of ValiRx commented: "The work we have done with TheoremRx since signing the Letter of Intent in November 2021 has involved both the negotiation and finalisation of documents between TheoremRx, ValiRx and CRT, but has also started the process of vendor selection for the next VAL201 clinical trial. This next trial will be sponsored and financed by TheoremRx, but ValiRx will continue to play a supporting role, providing project management and scientific expertise to ensure the trial runs smoothly in exchange for regular payments from TheoremRx. "

Progress being made. Highly unlikely that TheoremRx would have signed if funding was unlikely. The standard legal caveats the lawyers have placed in the RNS are now being used by the derampers to scare unconfident holders into selling. IMHO

Lets hope Tiziana and Accustem can get above their current farcical levels. I last sold a chunk of TILS at 260 p in Juy 2020, and subsequently bought at a bargain level of 180p!!! LOL. Its now at an equivalent of 40p.
What a pair of value additions GC and KS are, no wonder they are hiding!

Gina Rhinehart, eh? One of a handful of Aussies who stitched up the Sirius Minerals investors (along with Marc Cutifani of Anglo and Chris Fraser of Sirius?

Thanks but no thanks.

https://www.smh.com.au/business/companies/gina-rinehart-backed-sirius-minerals-succumbs-to-anglo-american-bid-20200120-p53t5q.html

Very wise. A lot mining juniors are down just due to lack of liquidity and interest past the Robinhood induced frenzy of this time last year. Even a little interest returning to this sector should see a rerate, but ROCK does need some good news.
Let's hope they have a good run of results and news this year.

2021 gold pour:
Q1 18725 oz with 81.9% recovery
Q2 16591 oz with 80% recovery
Q3 19456 oz at 84.4% recovery
So with 54772 oz produced to end Q3, just 16000 Oz in Q4 will take us over 70000 oz for the year, versus mid-year predictions of a total 64-69000 oz for annual production. They are already achieving close to the 85% "attainable recovery" CfC mentioned, so the company tweaks to BIOX are having some success, and I don't necessarily see that as an upper limit.

Look forward to the next update.
GLA

Fantastic news? Not for the Italian consumer.
Same thing happening in the UK, again due to shortsighted energy policies.

Happy New Year all.
Looks like we can forecast 2 million pounds a year of profit from electricity generation. Not bad at all.
Once we add in oil and gas sales, our market cap is going to look a little low.
Z

Yep, 2021 was a real annus horribilis.
I never imagined that the Accustem and Tiziana corporate actions would be so botched.

Happy New Year all,
The gold recovery of 20% seems very low, but better they caught the agglomeration issues early on and can hopefully rectify them.
I would expect recovery rates to be much higher once problems are addressed. I don't see why 90% should not be achievable. Am l being too optimistic?

Rockz, hope the momentum on nasdaq continues.
Still unable to trade TLSA on HL. Same goes for Accustem.

Happy New Year all.
Reposting from Friday, my notes on GC latest video for those who havent seen it yet.

Dechert Healthcare Deals Conference: Capital Markets | Strategies for Success in European and the U.S.
Held on Thursday, 23 September 2021, this year's in-person event was held at BMA House, Tavistock Square in London.
Added to You Tube on 11/11/2021
https://www.youtube.com/watch?v=MVP8XyJruDw

The whole discussion is interesting but I have highlighted Gabrieles comments in my very brief notes below.
I hope this is useful viewing for other long-suffering investors.
Happy New Year, hopefully.
ZB

3:00 to 3:47 minutes
He has founded Biovitas Capital biotech incubator in 2000 to bridge capital between Euro tech and US money. Founded 10 companies, listed 9, 7 on NASDAQ, 2 in London. Guess that leaves Accustem in Limbo!

15:24 {Gabe is asked for his perspective on dual listed companies] to 19:00 minutes
"Better to be dual-listed than single listed in London....liquidity is 50 to 1, investors are 100 to 1". Dechert are the genius legal firm behind the delisting too.
"Think our London listing drags down our NASDAQ price". Not BOD and delisting advisor incompetence?
"US institutions love simple, clean stories"
Interesting listen - he did not like his AIM experience.

25:19 minutes to 27:35 minutes
"Better to list on UK markets than use VC funds"
"Enjoyed standard listing more than AIM".......he criticises the traffic stop system on AIM, saying it knocked down the share price. "The AIM for us was a natural drag on the share price"

29:06 to 30:40 minutes
Gabriele discusses US liquidity vs Europe and criticises AIM again.

37:18 to 38:12 mins {Pros and Cons of Dual Listing }
GC:" increase liquidity and exposure to cross-Atlantic investors....its a no-brainer to have a dual listing"
"ADRs/ADS expensive but worth it for many investors"

38:12 {Asked about single listing in the US and the process}
GC: " alleviate ability for arbritrage, confusion, simplifly the story"

UK want 300 million LFT tests a month, US 500 million.
How many of those will be Paraytecs?
Look forward to the next RNS.
Happy New Year all!

Looking forward to lots of news in 2022. Shares at this level are a very good entry point considering the risk/reward here.

Lets hope our BOD read a couple of mining textbooks and start digging soon.